# Japanese Study of the Combined Administration of Docetaxel With Prednisolone for Metastatic Hormone Refractory Prostate Cancer

> **NCT00723086** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 16 (actual)

## Conditions studied

- Therapy, Prostatic Neoplasms

## Interventions

- **DRUG:** docetaxel (XRP6976)

## Key facts

- **NCT ID:** NCT00723086
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2009-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00723086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00723086, "Japanese Study of the Combined Administration of Docetaxel With Prednisolone for Metastatic Hormone Refractory Prostate Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00723086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*